Tumor-associated antigen epitope peptide and use thereof
Through tumor-related antigen epitope peptides derived from embryonic stem cells, the T cell response is stimulated, and the problem of insufficient immunogenicity of existing tumor vaccines is solved, effectively inhibiting bladder cancer and individualized treatment of multiple cancers is achieved.
Patent Information
- Application Number
- PCT/CN2023/141695
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2023-12-25
- Publication Date
- 2024-11-21
AI Technical Summary
The existing tumor vaccines have weak immunogenicity, which leads to immune escape from tumor cells, which leads to poor tumor suppression effect. Especially among the most challenging types of cancers such as bladder cancer, traditional treatments are highly invasive and It cannot meet the needs of individual diagnosis and treatment.
Tumor-related antigen epitope peptides derived from embryonic stem cells, including CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, NUF-2 and other antigens, and these antigen epitope peptides stimulate specific T cell production. A strong immune response that inhibits tumor growth is used to prepare drugs that inhibit tumor cell growth or stimulate T cell response.
Effectively inhibit the growth of bladder cancer in mouse models, significantly improve the IFN-γ secretion level and immune response of T cells, and provide a safe and efficient individualized treatment plan suitable for bladder cancer and many other cancer types .
Smart Images

Figure CN2023141695_21112024_PF_FP_ABST
Abstract
Description
Tumor-associated antigen epitope peptides and their applications Technical Field
[0001] The present invention belongs to the field of biotechnology and relates to tumor-associated antigen epitope peptides and applications thereof. Background Art
[0002] According to the latest statistics from IARC, the International Agency for Research on Cancer under the World Health Organization, bladder cancer ranks as the tenth most common type of cancer in the world. Every year, approximately 600,000 people are diagnosed with bladder cancer worldwide, and more than 200,000 die from the disease. Bladder cancer is one of the most challenging cancers to diagnose and treat. Its diagnosis mainly relies on cystoscopy, which is an invasive and expensive method. Currently, traditional treatments for cancer include surgery, radiotherapy, and chemotherapy. Although traditional treatments can effectively cure cancer, they cause great damage to the immune system and cannot meet the needs of personalized diagnosis and treatment. Emerging immunotherapies represented by vaccines, monoclonal antibodies, and adoptive T cell therapy have made tremendous progress in the past few decades, which have effectively compensated for the shortcomings of traditional therapies. A large number of studies have entered the clinical trial evaluation stage, and single or combined regimens can provide patients with more effective solutions.
[0003] Unlike traditional preventive vaccines, which stimulate immune responses with exogenous antigens, cancer vaccines target endogenous intracellular antigens and may trigger new tumor-specific immune responses, thereby exerting therapeutic effects. The earliest therapeutic cancer vaccines date back to the early 20th century, using killed Streptococcus and Serratia bacteria to treat malignant tumors. Today, cancer vaccines have become a promising candidate for solid tumor immunotherapy, stimulating antitumor immunity through the delivery of tumor antigens in the form of whole cells, peptides, or nucleic acids. Tumor antigens are categorized as tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are expressed exclusively in tumor cells and not in normal cells, while TSAs are expressed in both tumor and normal cells, but are highly expressed in tumor cells. Cancer vaccines are divided into two categories based on whether the antigens are defined prior to treatment: predefined and anonymous. Predefined antigens are further categorized as personalized and shared, depending on the frequency of expression of the antigen in patients with the same tumor type. Shared vaccines are applicable to a wide range of patient groups and can be evaluated through standard detection methods (cytology, immunohistochemistry, flow cytometry, etc.), so they can target both TSAs and TAAs. Cancer vaccines work mainly through the recognition and uptake of tumor antigens by antigen-presenting cells (APCs), which are then presented to CD8+ T cells (also known as cytotoxic T lymphocytes) through HLA-1. Subsequently, CD8+ T cells secrete a variety of cytokines (such as IFN-γ) to induce the body's immune response and kill tumors. In summary, due to the weak immunogenicity of current tumor vaccines, the immune escape of tumor cells leads to poor tumor vaccine effectiveness, resulting in poor tumor suppression effect.
[0004] Summary of the Invention
[0005] Based on this, it is necessary to provide a tumor-associated antigen epitope peptide that can be used to prepare tumor-associated antigen epitope peptides that can inhibit tumor cell growth or stimulate tumor cells to produce T cell responses and their applications.
[0006] A tumor-associated antigen epitope peptide, wherein the tumor-associated antigen epitope peptide is derived from embryonic stem cells, and the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
[0007] Research has found that among at least one embryonic stem cell-derived tumor-associated antigen selected from CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the ESC-expressed tumor-associated antigens KIF4A and NUF-2 can effectively inhibit bladder cancer growth. Furthermore, the ESC-expressed tumor-associated antigens CENPM, NUF-2, and IQGA3 can strongly stimulate specific T cell immune responses, manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, exerting a certain therapeutic effect. These antigens can be used to develop drugs that inhibit tumor cell growth or stimulate T cell responses in tumor cells. In vivo experiments have confirmed the vaccine's inhibitory effect on bladder cancer in mice.
[0008] In some embodiments, the tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences shown as SEQ ID No. 1 to SEQ ID No. 10.
[0009] In some embodiments, the tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences shown as SEQ ID No. 11 to SEQ ID No. 20.
[0010] The use of the above tumor-associated antigen epitope peptide in the preparation of drugs for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses.
[0011] In some embodiments, the tumor comprises at least one of bladder cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, and uterine cancer.
[0012] A drug for treating tumor-related diseases, comprising: at least one of the above-mentioned tumor-related antigen epitope peptides.
[0013] In some embodiments, in the drug for treating tumors, the tumor-associated antigen epitope peptide contains a peptide segment with an amino acid sequence as shown in SEQ ID No. 10 or a peptide segment with an amino acid sequence as shown in SEQ ID No. 20.
[0014] In some embodiments, in the drug for treating tumors, the tumor-associated antigen epitope peptide contains a first peptide segment and a second peptide segment, the first peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.9 and the amino acid sequence shown in SEQ ID No.19, and the second peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.8 and the amino acid sequence shown in SEQ ID No.18.
[0015] In some embodiments, the present invention further comprises an adjuvant, wherein the adjuvant comprises at least one of CpG oligodeoxynucleotide and Poly IC.
[0016] In some embodiments, a pharmaceutically acceptable carrier and / or excipient is also included.
[0017] The invention relates to the use of antigen epitope peptides derived from embryonic stem cells in the preparation of drugs for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses, wherein the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIG1 is a flow chart of the experimental operation of Example 1;
[0019] FIG2 is a graph showing the tumor growth inhibition test results of antigen epitope peptides derived from various genes in the experiment;
[0020] FIG3 is a graph showing the results of the detection of the inhibitory effect of the effective antigen epitope peptide mixed peptide vaccine on tumor growth in Example 1;
[0021] FIG4 is a graph showing the test results of the effect of mixed peptides on immune cells in the blood;
[0022] FIG5 is a graph showing the results of detecting the ability of specific T cells to secrete IFN-γ induced by tumor antigen epitope peptides. DETAILED DESCRIPTION
[0023] To make the above-mentioned objects, features, and advantages of the present invention more readily apparent, the following detailed description of the specific embodiments of the present invention is provided in conjunction with specific embodiments and accompanying drawings. The following description sets forth numerous specific details to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways than those described herein, and those skilled in the art may make similar modifications without departing from the scope of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.
[0024] The present application provides a tumor-associated antigen epitope peptide, which is derived from embryonic stem cells, wherein the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
[0025] The potential for stem cell vaccines to treat cancer stems from early observations that embryonic / fetal tissue immunity leads to rejection of transplanted tumors in animals. Subsequent studies have further demonstrated that inoculation of embryonic material in animals can induce cellular and humoral immunity against transplantable tumors and carcinogen-induced tumors. The similarity of antigens between tumor cells and embryonic cells (i.e., shared antigens) underlies their hypothesis as a cancer vaccine. Following three weeks of continuous inoculation with hepatic stem cells (HSCs) or embryonic stem cells (ESCs), Hepatocellular carcinoma cells (Hepa 1-6) were subcutaneously inoculated one week (Group 1) and four weeks (Group 2) after inoculation. Mice immunized with the HSC vaccine showed no tumor formation within one week, while only 10% of mice immunized with the ESC vaccine developed tumors. However, in the control group, the tumor formation rate reached 60%. When long-term memory responses were examined, the results in Group 2 were similar to those in Group 1. Experiments conducted during the same period demonstrated that in a subcutaneous liver cancer mouse model, 80% of mice receiving HSC vaccination completely eliminated their tumor burden, but 40% of mice receiving ESC vaccination developed tumors that did not increase in size over time. These data support the superior performance of stem cells as preventive or therapeutic cancer vaccines. However, the development of embryonic / fetal materials into vaccines for clinical use may face certain limitations, such as ethical considerations, tumorigenicity, and alloimmunization. Autologous iPSCs (Induced Pluripotent Stem Cells, iPSCs) can also be used directly as vaccines after irradiation, and their emergence is overcoming these limitations. Notably, single iPSC immunization does not exert a strong anti-tumor effect, but the combined use of CpG as an adjuvant solves this problem, with tumor suppressor effects verified in breast cancer, melanoma, and mesothelioma.
[0026] Centromere protein M (CENPM), encoded by the gene CENPM, is involved in kinetochore assembly and chromosome segregation, playing a crucial role in the cell cycle. Recent research has focused on its association with cancer. CENPM promotes tumorigenesis through multiple pathways, including p53 and mTOR / p70S6k. Kinetochore protein 2 (NUF2), encoded by NUF2, is associated with centromeres and involved in chromosome segregation. Similarly, upregulation of NUF2 promotes tumorigenesis, and altered NUF2 levels affect cell proliferation, migration, and invasion. The chromosome-associated molecular motor (KIF4A), encoded by KIF4A, a member of the kinesin superfamily, participates in intracellular transport and is responsible for maintaining cellular morphology. Furthermore, it is involved in chromosome assembly and segregation during mitosis. Similarly, altered KIF4A levels are associated with tumor progression. These findings suggest that these proteins have the potential to serve as predictive biomarkers for cancer prognosis; however, relatively few reports exist on their use as antigenic peptides.
[0027] Research has found that among at least one embryonic stem cell-derived tumor-associated antigen selected from CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the ESC-expressed tumor-associated antigens KIF4A and NUF-2 can effectively inhibit bladder cancer growth. Furthermore, the ESC-expressed tumor-associated antigens CENPM, NUF-2, and IQGA3 can strongly stimulate specific T cell immune responses, manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, exerting a certain therapeutic effect. These antigens can be used to develop drugs that inhibit tumor cell growth or stimulate T cell responses in tumor cells. In vivo experiments have confirmed the vaccine's inhibitory effect on bladder cancer in mice.
[0028] In some embodiments, the tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences shown as SEQ ID No. 1 to SEQ ID No. 10.
[0029] In some embodiments, the tumor-associated antigen epitope peptide comprises one of the peptide segments with amino acid sequences as shown in SEQ ID No. 11 to SEQ ID No. 20. The peptide segments with amino acid sequences as shown in SEQ ID No. 11 to SEQ ID No. 20 are extended peptides of the peptide segments with amino acid sequences as shown in SEQ ID No. 1 to SEQ ID No. 10, and the two are essentially functionally identical. Because dendritic cells require a cleavage process when presenting antigen epitopes, extended peptides comprising the peptide segments with amino acid sequences as shown in SEQ ID No. 1 to SEQ ID No. 10 are synthesized during actual synthesis.
[0030] One embodiment of the present study also provides a drug for treating tumors, comprising: at least one of the above-mentioned tumor-associated antigen epitope peptides.
[0031] Traditional methods, such as surgery, radiotherapy and chemotherapy, are invasive and have good effects on tumors that have not spread in the early stages, but they cause indiscriminate and irreversible damage to the human body and the human immune system, increasing the risk of contracting other diseases. Immune checkpoint inhibitors have improved the prognosis of people who are intolerant to chemotherapy, but they face the problem of low overall response rate in patients in clinical applications and the risk of inducing fatal immune-related side effects. Adoptive T cell therapy (such as Chimeric Antigen Receptor T-Cell, CAR-T) can quickly induce the body's immune response while bringing strong toxicity. In addition, the time cost and high cost of transformation and re-infusion, as well as off-target and antigen escape, also limit the application of this technology. Cancer vaccines have the advantages of high safety and few side effects due to their clear mechanism of action and known antigen targets. The present invention aims to expand the process of stem cell-based cancer vaccine epitope identification and system preparation, and accelerate the construction of vaccine discovery platforms.
[0032] Research has found that among at least one embryonic stem cell-derived tumor-associated antigen selected from CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2, the ESC-expressed tumor-associated antigens KIF4A and NUF-2 can effectively inhibit bladder cancer growth. Furthermore, the ESC-expressed tumor-associated antigens CENPM, NUF-2, and IQGA3 can strongly stimulate specific T cell immune responses, manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, exerting a certain therapeutic effect. Tumor-related drugs prepared from these tumor-associated antigen epitope peptides can inhibit tumor cell growth or stimulate tumor cells to produce T cell responses. In vivo experiments have verified that the vaccine has an inhibitory effect on bladder cancer in mice.
[0033] In some embodiments, the tumor comprises at least one of bladder cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, and uterine cancer.
[0034] In some embodiments, the tumor-associated antigen epitope peptide in the drug for treating tumors contains a peptide segment with an amino acid sequence such as SEQ ID No. 10 or a peptide segment with an amino acid sequence such as SEQ ID No. 20. Experimental verification has shown that the tumor-associated antigen epitope peptide in the drug can induce a strong T cell response and a significant tumor inhibitory effect, and can be used as an anti-tumor drug.
[0035] In some embodiments, the tumor-associated antigen epitope peptide in the drug for treating tumors comprises a first peptide segment and a second peptide segment, wherein the first peptide segment comprises at least one of the amino acid sequence shown in SEQ ID No. 9 and the amino acid sequence shown in SEQ ID No. 19, and the second peptide segment comprises at least one of the amino acid sequence shown in SEQ ID No. 8 and the amino acid sequence shown in SEQ ID No. 18. Experimental verification has shown that the tumor-associated antigen epitope peptide in the drug has a significant tumor inhibitory effect.
[0036] In some embodiments, the drug for treating tumors further comprises an adjuvant, wherein the adjuvant comprises at least one of a CpG oligodeoxynucleotide and a poly IC. With the aid of such an adjuvant, the anti-tumor effect of the tumor-associated antigen epitope peptide or the effectiveness of treating tumors can be enhanced. The tumor may be bladder cancer.
[0037] In some embodiments, the drug for treating tumors further comprises a pharmaceutically acceptable carrier and / or excipient. The pharmaceutically acceptable carrier and / or excipient, for example, comprises a solvent, and the solvent may be, for example, DPBS. It should be noted that the pharmaceutically acceptable carrier and / or excipient are not limited to the above-mentioned ones, and corresponding pharmaceutically acceptable carriers and / or excipients may be selected as needed.
[0038] In some embodiments, the drug for treating tumors is a vaccine.
[0039] Among the above-mentioned drugs for treating tumors, vaccines prepared from tumor-associated antigens KIF4A-1, KIF4A-2, and NUF-2 expressed by ESCs can effectively inhibit the growth of bladder cancer. CENPM and NUF-2 can strongly stimulate the immune response of specific T cells, which is manifested by stimulating peptide-specific CTLs to secrete high levels of IFN-γ and inhibit tumor growth, exerting a certain therapeutic effect.
[0040] Furthermore, among the aforementioned tumor-related drugs, individual peptides CENPM, NUF-2, KIF4A-1, and KIF4A-2, which exhibit anti-cancer effects, were formulated into peptides and used as vaccines to immunize mice. The combination demonstrated promising anti-cancer efficacy. Furthermore, the selected peptides, when combined with the adjuvant CpG oligodeoxynucleotide (CPG-ODN), demonstrated limited efficacy in the treatment of bladder cancer. Embryonic stem cell-derived peptides can be used in the preparation of therapeutic peptide vaccines for tumors.
[0041] The present application provides several tumor-associated antigens (TAAs) expressed by embryonic stem cells (ESCs) as potential therapeutic TAAs and effective epitopes, which can be used to prepare a shared vaccine that effectively inhibits bladder cancer growth, has high safety, few toxic side effects, and high specificity.
[0042] The following is a specific example section.
[0043] Unless otherwise specified, the reagents and instruments used in the examples are all conventionally selected in the art. Experimental methods for which specific conditions are not specified in the examples are generally carried out under conventional conditions, such as those described in the literature or books, or methods recommended by the kit manufacturer. The reagents used in the examples are all commercially available.
[0044] In the following examples, unless otherwise specified, the protein and epitope peptide sequences screened out in Example 1 are shown in Table 1.
[0045] Table 1 Proteins and epitope peptide sequences screened in Example 1
[0046] In Table 1, the extended peptide contains the epitope peptide sequence and is functionally the same as the epitope peptide. Because dendritic cells require a cleavage process when presenting antigen epitopes, extended peptides containing epitope peptides are actually synthesized; population coverage refers to the proportion of people in the population who have at least one HLA allele that can bind to the peptide segment.
[0047] Example 1
[0048] This example uses a predictive immunoinformatics algorithm to predict shared genes that are highly expressed in ESCs and tumor cells but very low in normal tissues. It then predicts the antigenic epitope peptides of CD8+ T cells that highly express these genes. CENPM, KIF4A-1, KIF4A-2, and NUF-2 are selected as potential therapeutic TAAs and effective epitopes. Vaccines based on these antigens are designed, and their sustained tumor growth inhibition in a mouse model of bladder cancer is verified. The immune response of antigen-specific T cells is assessed using an enzyme-linked immunosorbent assay (ELISPOT).
[0049] As shown in FIG1 (FIG. 1 is a flow chart of the test operation of this embodiment), the specific operation process of this embodiment is as follows:
[0050] (1) Screening of therapeutic TAAs and effective epitopes:
[0051] By performing RNA-seq sequencing on ESC (129) cell lines, bladder cancer cell lines (MB49), liver cancer cell lines (ML-1), and lung cancer cell lines (LLC), the expressed genes were compared with the cancer cell line MB49 and healthy tissues, and shared genes that were highly expressed in ESCs but very lowly expressed in normal tissues were screened as potential therapeutic TAAs.
[0052] By sequencing and analyzing the transcriptomes of mouse tumor cells and embryonic stem cells, we obtained genes that are highly expressed in both tumor cells and embryonic stem cells, numbered 1-10. After literature research and in vitro experimental verification, we screened out effective genes, including Pep-1 (cenpm), Pep-8 (kif-4a-1), Pep-9 (kif-4a-2), and Pep-10 (nuf-2). We also obtained the antigenic epitopes of these genes through analysis, and collaborated with Gill Biochemical (Shanghai) Co., Ltd. to synthesize extended peptides containing the antigenic epitope peptides of these genes.
[0053] (2) Preparation of tumor vaccines and evaluation of their therapeutic potential:
[0054] Cancer cells and animal models: MB49 bladder cancer cells were grown in DMEM containing 10% FBS (Fetal Bovine Serum, Gibco, 10099141C) and 1% PS (Penicillin-Streptomycin-Glutamine, Gibco, 10378016). 5 MB49 cancer cells were resuspended in 100 μL of DPBS and injected subcutaneously into the lower back of male C57BL / 6 mice (6-8 weeks old) to establish a mouse bladder cancer treatment model. Tumors formed in the mice approximately 5 days after initial inoculation. Tumor growth was monitored every 3 days. The long diameter (a) and short diameter (b) of the tumors were measured with a vernier caliper. The volume of each solid tumor was calculated using the formula (V) = a × b × b / 2, and tumor growth curves were plotted.
[0055] Vaccine Preparation and Periodic Vaccination: Tumor-bearing mice were randomly divided into the following groups: DPBS (phosphate-buffered saline) group, CpG group, CpG + CENPM group, CpG + IQGA3-1 + IQGA3-2 group, CpG + KIF4A-1 + KIF4A-2 group, and CpG + NUF-2 group, with 6 mice per group. Using DPBS (phosphate-buffered saline) as the solvent and CpG ODN 1826 as the vaccine adjuvant, vaccines were prepared according to group. The final concentration of CpG ODN 1826 was 10 μM, and the final concentration of each peptide was 100 μg / 100 μL. The volume was adjusted to 100 μL with DPBS and injected subcutaneously at the back of the neck of the mice. The first vaccination was performed on Day 3, and the same vaccine was administered every 3 days thereafter for a total of 7 doses.
[0056] Preparation of spleen single cell suspension: The dissected spleen was crushed and then collected through a 70 μm cell sieve into a 15 mL centrifuge tube. The red blood cells were lysed with 1 mL of lysis buffer to stop lysis. The cells were then washed with DPBS and counted for ELISPOT.
[0057] Isolation of Tumor-Infiltrating Lymphocytes (TILs): On Day 26, mice were anesthetized and sacrificed, and solid tumors were removed. Tumors were minced and suspended in 5 mL of digestion buffer (50 mL of HBSS containing 2 mg / mL Collagenase A and 50 units / mL DNase I) and incubated in a water bath at 37°C, 180 rpm, for 20 min. Digested tumor fragments were collected through a 100 μm cell sieve into a 50 mL centrifuge tube and digestion was terminated with wash buffer containing EDTA. Cells were separated by centrifugation at 400 g for 25 min using 40% and 80% Percoll. The intermediate lymphocytes were collected and washed with DPBS. The cells were counted for ELISPOT analysis.
[0058] ELISPOT analysis: Splenocytes were isolated as described above and 5×10 5 The cells were co-cultured with different peptides (10 μg) for 20 h. The size and number of IFN-γ positive spots were calculated using Adobe Photoshop CS6 software.
[0059] Data analysis: Data were analyzed using GraphPad Prism. All values in bar graphs and curves are expressed as mean ± SEM. Differences between groups were assessed using conventional one-way ANOVA or unpaired t test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
[0060] The experimental results are shown in Figures 2 to 5.
[0061] Figure 2 shows the results of tumor growth inhibition test of antigen epitope peptides derived from various genes. In Figure 2, all mice were injected subcutaneously with 3×10 5 MB49 bladder cancer cells were immunized with peptides on days 3, 6, 9, 12, 15, 18, and 21, and mice were euthanized on day 26. Each mouse in the experimental group received a subcutaneous injection of a synthetic epitope peptide plus the adjuvant CpG, with a total injection volume of 100 μl per mouse, and the amount of CpG was 10 μM. Tumor size was measured every three days after peptide immunization. As shown in Figure 2, tumor size was significantly suppressed in the KIF4A-1 / -2 and NUF-2 groups after immunization with different peptides. CENPM had a partial tumor growth inhibitory effect, while the other groups had no significant inhibitory effect on bladder cancer.
[0062] Figure 3 shows the results of testing the inhibitory effect of the mixed peptide vaccine on tumor growth by mixing the above-mentioned effective antigen epitope peptides. In Figure 3, all mice were subcutaneously injected with 3×10 5MB49 bladder cancer cells were immunized with peptides on days 3, 6, 9, 12, 15, 18, and 21, and mice were euthanized on day 26. Each mouse in the experimental group received a subcutaneous injection of a synthetic epitope peptide with the adjuvant CpG. The vaccine peptides contained KIF4A-1 / -2, NUF-2, and CENPM, dissolved in 100 μL DPBS with 10 μM CpG adjuvant. A total of 100 μL was injected per mouse. Tumor size was measured every three days after peptide immunization. As shown in Figure 3, after immunization with different peptides, the mixed peptide group exhibited significant tumor growth inhibition.
[0063] Figure 4 shows the test results of the mixed peptides on immune cells in the blood. In Figure 4, all mice were injected subcutaneously with 3×10 5 MB49 bladder cancer cells were immunized with a mixed peptide plus adjuvant on days 3, 6, 9, 12, 15, 18, and 21. Mice were euthanized on day 26. Peripheral blood was collected from the mice at sacrifice, and 100 μL of blood was stained with antibodies for CD45, CD4, CD44, CD25, and FOXP3. The proportions of CD4 memory cells and Treg cells in the blood were analyzed using multi-color flow cytometry. As shown in Figure 4, after immunization with the mixed peptide, the proportion of memory T cells was significantly increased, while Treg cells were significantly suppressed.
[0064] Figure 5 shows the results of testing the ability of specific T cells to secrete IFN-γ induced by tumor antigen epitope peptides. In Figure 5, test mice were euthanized, spleen tissue was aseptically removed, ground, and monocytes were isolated using lymphocyte separation fluid. Monocytes were incubated in ELISPOT plate wells and stimulated simultaneously. Culture and cytokine capture were performed in a 37°C incubator. After 20 hours, spot formation was detected to measure the number of T cells specifically secreting IFN-γ in the spleen cells of the immunized mice. As shown in Figure 5, mice immunized with epitope peptides can induce IFN-γ-related T cell immune responses.
[0065] Combined with the above figures, in vivo experiments verified the vaccine's inhibitory effect on bladder cancer in mice. In this mouse bladder cancer model, cyclic vaccine treatment was administered every three days, starting on day three after tumor inoculation, for a total of seven times. Tumor growth curves and solid tumor images (Figure 1) show that the peptide-containing vaccines all reduced tumor growth to varying degrees compared to the control DPBS and CpG groups. With the help of CpG, the KIF4A-1 + KIF4A-2 combination vaccine and the NUF-2 vaccine significantly inhibited bladder cancer tumor growth. However, the CENPM and combined IQGA3-1 + IQGA3-2 vaccines did not show significant tumor inhibition. IFN-γ ELISPOT analysis of mouse spleen cells showed that the CENPM and NUF-2 peptides stimulated significant T cell responses in spleen cells compared to the control DPBS and CpG groups.
[0066] In summary, the NUF-2 vaccine induced the strongest T cell response and the most significant tumor suppression, demonstrating its potential as a cancer vaccine. Notably, CENPM induced a T cell response but did not exhibit strong anti-tumor effects. Furthermore, the KIF4A-1 + KIF4A-2 combination vaccine, which effectively inhibited tumor growth, did not elicit a strong T cell response when stimulated by the peptides alone. This suggests that multi-antigen vaccines are more effective than single-antigen vaccines in inhibiting cancer progression.
[0067] This application screened multiple genes co-expressed by tumor cells and stem cells and predicted and analyzed the epitope peptides and extended peptides expressed by these genes. These peptides, synthesized in vitro, were shown to effectively inhibit bladder cancer tumor growth while activating a strong T cell-specific immune response. Animal experiments demonstrated that these ESC-derived epitope peptides have a potent immunotherapeutic effect against bladder cancer.
[0068] This application, combined with animal experiments, verifies the reliability of potential tumor-associated antigens TAAs and epitopes previously predicted by bioinformatics algorithms based on the anti-tumor effects of ESCs as vaccines for the treatment of bladder cancer. The program provides a complete set of processes, from the initial screening of tumor-specific antigens, the preparation and vaccination of epitope peptide vaccines, and subsequent immunological experimental analysis to test their effectiveness. In addition, the program configures the individual peptide segments CENPM, NUF-2, KIF4A-1, and KIF4A-2 that have been previously obtained and pre-experimentally verified to have anti-cancer effects into polypeptides, which are used as vaccines to immunize mice, and the combination shows good anti-cancer efficacy. The disclosed technical route is easy to reproduce, shortens the discovery and verification cycle, and greatly enhances the application potential of stem cell-based gene epitope vaccines as therapeutic tumor vaccines in the context of precision medicine.
[0069] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the patent for this invention shall be determined by the appended claims.
Claims
1. A tumor-associated antigen epitope peptide, characterized in that: The tumor-associated antigen epitope peptide is derived from embryonic stem cells, and the tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
2. The tumor-associated antigen epitope peptide according to claim 1, characterized in that: The tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences as shown in SEQ ID No.1-SEQ ID No.
10.
3. The tumor-associated antigen epitope peptide according to any one of claims 1 to 2, characterized in that: The tumor-associated antigen epitope peptide contains one of the peptide segments with amino acid sequences as shown in SEQ ID No.11-SEQ ID No.
20.
4. Use of the tumor-associated antigen epitope peptide according to any one of claims 1 to 3 in the preparation of a drug for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses.
5. The use according to claim 4, characterized in that: The tumor includes at least one of bladder cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, and uterine cancer.
6. A drug for treating tumors, characterized in that: include: At least one of the tumor-associated antigen epitope peptides according to any one of claims 1 to 3.
7. The drug for treating tumors according to claim 6, characterized in that: In the drug for treating tumors, the tumor-associated antigen epitope peptide contains a peptide segment with an amino acid sequence as shown in SEQ ID No. 10 or a peptide segment with an amino acid sequence as shown in SEQ ID No. 20; Alternatively, in the drug for treating tumor-related diseases, the tumor-associated antigen epitope peptide contains a first peptide segment and a second peptide segment, the first peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.9 and the amino acid sequence shown in SEQ ID No.19, and the second peptide segment contains at least one of the amino acid sequence shown in SEQ ID No.8 and the amino acid sequence shown in SEQ ID No.
18.
8. The drug for treating tumors according to claim 6, characterized in that: Also included is an adjuvant, which includes at least one of CpG oligodeoxynucleotide and Poly IC.
9. The drug for treating tumors according to any one of claims 6 to 8, characterized in that: Also included are pharmaceutically acceptable carriers and / or excipients.
10. Use of antigen epitope peptides derived from embryonic stem cells in the preparation of drugs for inhibiting tumor cell growth and / or stimulating tumor cells to produce T cell responses, characterized in that: The tumor-associated antigen is selected from at least one of CENPM, IQGA3-1, IQGA3-2, KIF4A-1, KIF4A-2, and NUF-2.
Citation Information
Patent Citations
IQGAP3 epitope peptides and vaccines containing the same
CN102119169A
HLA-A11 restricted and carcino-embryonic antigen originated epitope peptide and application thereof
CN105753978A
Centromere / kinetochore protein genes for cancer diagnosis, prognosis and treatment selection
CN106661624A
CDCA1-derived peptide and vaccine containing same
CN112839950A
Key marker for indicating drug resistance of liver cancer to 5-fluorouracil and screening method
CN112946275A
